Acute clinical tolerance of creatinol O-phosphate

Acute clinical tolerance to N-methyl-N-(beta-hydroxyethyl) guanidine O-phosphate (creatinol O-phosphate, COP) was investigated in volunteer human subjects without heart or renal disease and without other serious illness. COP was administered i.v. at three different dosages, 1020 mg (group A), 2040 m...

Full description

Saved in:
Bibliographic Details
Published inArzneimittel-Forschung Vol. 29; no. 9a; p. 1447
Main Authors Melloni, G F, Minoja, G M, Lureti, G F, Merlo, L, Pamparana, F, Brusoni, B
Format Journal Article
LanguageEnglish
Published Germany 1979
Subjects
Adolescent
Adult
Aged
Creatine - administration & dosage
Creatine - analogs & derivatives
Creatine - pharmacology
Diuresis - drug effects
Drug Tolerance
Female
Hemodynamics - drug effects
Humans
Injections, Intravenous
Male
Middle Aged
Time Factors
Online AccessGet more information

Cover

More Information
Summary:Acute clinical tolerance to N-methyl-N-(beta-hydroxyethyl) guanidine O-phosphate (creatinol O-phosphate, COP) was investigated in volunteer human subjects without heart or renal disease and without other serious illness. COP was administered i.v. at three different dosages, 1020 mg (group A), 2040 mg (group B) and 3060 mg (group C), in comparison with a placebo (group D). Arterial pressure, heart rate, ECG pattern and a complete blood analysis showed no change at any COP dosage, with the exception of blood phosphate, which increased in groups B and C. Cumulative urinary excretion of phosphate and creatinine and diuresis increased, whereas other urine parameters did not change. The phosphate and creatinine increases derived from the COP molecule and the increase in diuresis from a simple osmotic process required to dilute the phosphate in the tubular fluid. All these alterations were statistically significant and dose-related with COP and had been expected. COP proved to be a very well tolerated drug without any evident side effect.
ISSN:0004-4172